Clinical Innovation and Partnering World 2017 Day 1
08:50
Opening Remarks from the chair
09:00
'Putting patients at the heart of research'
09:20
Smart Technologies Transforming Patient Engagement: from Concept to Reality!
-
Automating clinical trial processes and personalizing patient support: the right pill for the right patient at the right time
-
An integrated suite of smart technologies, soon open for cross-pharma adoption
- Building the next generation of clinical trials
09:40
Engaging the patient by providing data access and inclusion in a trial community
- Engaging the patient by providing data access and inclusion in a trial community
- Discover how Janssen enabled patients get on-demand access to their data during the trial in order to promote transparency, engagement and retention
- Data access as part of a Global Trial Community to connect and engage with patients
10:00
“From a unit of innovation to an innovative pediatric hospital”
The idea is to explain how we changed the institution to become an innovative hospital, applied to the research and innovation department, showing different examples of innovation:
Introduction: our innovation model
- In the organisation: the clinical research unit and the KIDS program (patient’s involvement in the clinical trials design)
- In the projects (some examples below) :
o Social media applied to Rare Diseases Research : Rare commons https://www.rarecommons.org/en
o Telemedicine: Funny Friends
o Wearables as therapeutic intervention: the example of diabetes
CLINICAL LEADERS PANEL: The Good, The Bad, The Ugly of the Sponsor – CRO relationship
11:55
Delivering patient centred science
- To be patient centred, it’s important to understand how patients define patient centricity
- What does a patient centred framework look like
12:15
Simon Ridley, Director of Research, Myeloma UK
Robert Kroes, Project Lead of Clinical Open Innovation for Europe, Lilly
Patient Centricity in Clinical Trials
Simon Ridley, Director of Research, Myeloma UK
Robert Kroes, Project Lead of Clinical Open Innovation for Europe, Lilly
Developing a successful outsourcing strategy
13:59
Renaud Burrer, R&D Manager, Histalim
Chair's opening remarks
Renaud Burrer, R&D Manager, Histalim
Developing a successful outsourcing strategy
14:00
- Multiple vs singular CRO input
- Finding the balance between expertise and ethos
Ms Muna Kugler, Associate Director and Group Leader, Actelion Pharmaceuticals Ltd.
PANEL: Disruptive procurement methods: Choosing your CRO
- Multiple vs singular CRO input
- Finding the balance between expertise and ethos
Ms Muna Kugler, Associate Director and Group Leader, Actelion Pharmaceuticals Ltd.
Patient centricity
14:00
The UK Accelerated Access Review – a summary of recommendations, how patients can be involved and add to the process of innovation. The Accelerated Access Review aims to speed up access to innovative drugs, devices and diagnostics for NHS patients.
Accelerated Access Review
The UK Accelerated Access Review – a summary of recommendations, how patients can be involved and add to the process of innovation. The Accelerated Access Review aims to speed up access to innovative drugs, devices and diagnostics for NHS patients.
Patient centricity
14:20
- Getting the conversation going - initiatives to create a society that can enhance clinical research
- Priority setting - answering the questions that matter most
- Overcoming the challenges - making patient involvement work for the NHS, it's patients and our commercial partners
Patients as partners - transforming the delivery of clinical research in the NHS
- Getting the conversation going - initiatives to create a society that can enhance clinical research
- Priority setting - answering the questions that matter most
- Overcoming the challenges - making patient involvement work for the NHS, it's patients and our commercial partners
Developing a successful outsourcing strategy
14:40
Renaud Burrer, R&D Manager, Histalim
Innovation in a Histopathology Central Laboratory
Renaud Burrer, R&D Manager, Histalim
Developing a successful outsourcing strategy
15:10
Simon Ridley, Director of Research, Myeloma UK
Understanding how to partner with charities to deliver patient centric clinical trials
Simon Ridley, Director of Research, Myeloma UK The role of caregivers provide in clinical research
Effective planning and risk management
15:59
Case studies on disruptive technologies
15:59
Effective planning and risk management
16:00
- What regulators will expect in terms of compliance with the guideline
- Considerations for preparing how to address the changes required to effectively implement the revised guidelines
- Understanding how your RBM strategy fits into your overall quality management system
The Impact of ICH E6 (GCP) Addendum on sponsors and a Guide to Understanding how RBM fits In
- What regulators will expect in terms of compliance with the guideline
- Considerations for preparing how to address the changes required to effectively implement the revised guidelines
- Understanding how your RBM strategy fits into your overall quality management system
Case studies on disruptive technologies
16:20
- How are top 20 pharma companies currently already developing digital health solutions - beyond just trials? a look at key initiatives, partnerships, investments, and dedicated teams you are building up
- Which technologies attract venture investment: recent examples of investment in digital health technologies for clinical trials & beyond
- Removing the blinders; you should be aware of potential new entrants in the life sciences industry who could disrupt the entire pharma industry
Disrupting clinical trials: looking at the bigger picture:
- How are top 20 pharma companies currently already developing digital health solutions - beyond just trials? a look at key initiatives, partnerships, investments, and dedicated teams you are building up
- Which technologies attract venture investment: recent examples of investment in digital health technologies for clinical trials & beyond
- Removing the blinders; you should be aware of potential new entrants in the life sciences industry who could disrupt the entire pharma industry
Effective planning and risk management
16:30
A longitudinal case study following implementation of a RBM strategy for an early phase oncology portfolio
Case studies on disruptive technologies
16:40
Using emerging technologies to drive patient centricity into clinical trials
Effective planning and risk management
16:55
- What needs to be taken into account when implementing risk based monitoring
- What are the obstacles in the implementation process
- How to get started, via a big bang approach or via a stepwise approach
- What could go wrong and does it matter
Risk based monitoring: What could go wrong in my trial, from a data point of view?
- What needs to be taken into account when implementing risk based monitoring
- What are the obstacles in the implementation process
- How to get started, via a big bang approach or via a stepwise approach
- What could go wrong and does it matter
Case studies on disruptive technologies
17:00
Overcoming the challenges in implementing new technologies for clinical research
last published: 03/Mar/17 10:55 GMT
